Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
Min HuangYanyan LouJames PellissierThomas BurkeFrank Xiaoqing LiuRuifeng XuVamsidhar VelchetiPublished in: PharmacoEconomics (2018)
Pembrolizumab is projected to be a cost-effective option compared with SoC platinum-based chemotherapy as first-line treatment in adults with metastatic NSCLC expressing high levels of PD-L1.